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Abstract
Virstatin is a small molecule that inhibits Vibrio cholerae virulence regulation, the causative agent for cholera. Here we report
the interaction of virstatin with human serum albumin (HSA) using various biophysical methods. The drug binding was
monitored using different isomeric forms of HSA (N form ,pH 7.2, B form ,pH 9.0 and F form ,pH 3.5) by absorption and
fluorescence spectroscopy. There is a considerable quenching of the intrinsic fluorescence of HSA on binding the drug. The
distance (r) between donor (Trp214 in HSA) and acceptor (virstatin), obtained from Forster-type fluorescence resonance
energy transfer (FRET), was found to be 3.05 nm. The ITC data revealed that the binding was an enthalpy-driven process and
the binding constants Ka for N and B isomers were found to be 6.09610
5 M
21 and 4.47610
5 M
21, respectively. The
conformational changes of HSA due to the interaction with the drug were investigated from circular dichroism (CD) and
Fourier Transform Infrared (FTIR) spectroscopy. For 1:1 molar ratio of the protein and the drug the far-UV CD spectra showed
an increase in a- helicity for all the conformers of HSA, and the protein is stabilized against urea and thermal unfolding.
Molecular docking studies revealed possible residues involved in the protein-drug interaction and indicated that virstatin
binds to Site I (subdomain IIA), also known as the warfarin binding site.
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Introduction
Chemical genetics is an emerging field of research which
employs small molecules to dissect complex biological processes
and for studying microbial pathogenesis [1,2]. In order to dissect
the pathogenesis cholera, which still poses a threat to many parts
of the world, high throughput screen of 50,000 compounds in
small molecule library from Chembridge Research Laboratories
was carried out to identify inhibitors of Vibrio cholerae virulence
factor expression [3–6]. Virstatin, 4-[N-(1,8-naphthalimide)]-n-
butyric acid (Figure 1), is such a small molecule that attenuates the
intestinal colonization of Vibrio cholerae by preventing the dimer-
ization of the transcriptional activator ToxT [7,8]. It also binds to
accessory cholera enterotoxin (Ace), an important toxin of V.
cholerae [9]. In view of this, we planned to carry out the binding
studies of virstatin with human serum albumin (HSA), the most
abundant protein in the circulatory system. HSA is synthesized in
the liver, exported as a non-glycosylated protein and is present in
the blood at around 40 mg ml
21.
The most important physiological role of HSA is to bind a large
variety of ligands (fatty acids, hormones, amino acids, drugs, etc.),
and deliver them to the target organs. This remarkable binding
property of HSA account for the central role it plays in both the
efficacy and the rate of delivery of ligands, and hence has
stimulated a great deal of research on the nature of ligand binding
sites [10]. However, the binding of ligand depends on its molecular
and physical properties and hence all the ligands do not bind at the
same site of HSA. The X-ray crystallographic studies reveal that
the heart shaped HSA consists of three structurally similar
domains (I, II and III), each of which contains two subdomains
(A and B) [11,12]. These subdomains are predominantly helical
and extensively cross-linked through several disulfide bridges, with
one tryptophan residue (Trp214) in subdomain IIA [13,14]. It is
suggested that the principal regions of ligand binding to HSA are
located in hydrophobic cavities in subdomains IIA and IIIA,
which are designated as sites I and II, respectively [15,16].
To understand the pharmacological actions of a particular drug
and the relationship of its structure and function, the mode of
binding between the drug and the protein under different pH
conditions should be studied. Since HSA is known to undergo
different pH-dependent conformational transitions it is an ideal
candidate for studying protein-drug interaction [17]. At pH 7,
HSA assumes the normal form (N) which abruptly changes to a
highly charged fast migrating form (F) at pH values less than 4.3,
as this form moves ‘‘fast’’ upon gel electrophoresis [18]. The N-F
transition involves the unfolding and separation of domain IIIA
from the rest of the molecule without significantly affecting the rest
of the molecule [19,20]. Though the pH of blood is generally
stable, there is a difference in pH among blood, cerebral blood
flow and intracellular and extracellular environments where the
drug-HSA interaction takes place. So the transition states of the
HSA can affect the binding affinities of the drug, which in turn
influence the concentration of the drug in the blood, thereby
affecting its biological functions [21,22]. Moreover, serum
albumins are effective in increasing the solubility of hydrophobic
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37468drugs in plasma and thereby facilitate their delivery to cell in vivo
and in vitro.
In this study to explore the binding of virstatin to HSA (N, B
and F forms), UV absorption spectroscopy, steady-state fluores-
cence, quenching of tryptophan fluorescence and ITC measure-
ments were carried out. Moreover, far-UV CD, near-UV CD and
FT-IR spectroscopy was employed to confirm the conformational
changes of the protein upon drug binding. The probable binding
site of virstatin to HSA is also predicted from molecular docking
studies.
Materials and Methods
Materials
Both human serum albumin (free from fatty acid, CALBIO-
CHEM Cat# 126658) and virstatin (CALBIOCHEM Cat#
677520) were purchased from Merck, Germany and were used
without further purification. The stock solution of virstatin was
prepared in 100% DMSO. Spectroscopic sample of HSA was
prepared by weighing and dissolving the protein in different
buffers set at a given pH. For N, B and F conformational states of
protein 0.1 M potassium phosphate (pH 7.2 and 9.0) and 10 mM
acetic acid/sodium acetate (pH 3.5), respectively were used. The
exact concentration of HSA was determined spectrophotometri-
cally using molar extinction coefficient of 35700 M
21 cm
21 in a
UV-1800 Shimadzu Spectrophotometer. All the other chemicals
were of analytical grade and used as supplied without further
purification.
UV Spectroscopic Measurements
The UV absorption spectra of the drug along with HSA in the
molar ratio of 1:1 (10 mM) at pH 7.2 were recorded on a UV–
1800 Shimadzu spectrophotometer from 700–200 nm. Baseline
was corrected using 0.1 M potassium phosphate buffer pH 7.2.
Fluorescence Measurements and HSA Denaturation
Fluorescence spectra were measured with a Hitachi F–3010
spectrofluorimeter at 25uC with a 1 cm path length quartz
cuvette. Both the excitation and emission band passes were kept
at 2.5 nm. The excitation wavelength was set at 295 nm to
selectively excite the tryptophan residue. Binding of bis-ANS to
HSA was measured at 25uC using excitation at 395 nm using
slit widths of 5 nm and measuring the emission fluorescence
spectra between 420 and 600 nm. Bis-ANS was added to 5 mM
of HSA and the changes in ANS fluorescence were followed by
measuring the intensity at 495 nm. For energy transfer
experiments, an excitation wavelength of 295 nm was used to
selectively excite tryptophan residues. Quenching experiment of
HSA was performed with successive addition of virstatin and
the fluorescence values were corrected for the inner filter effect
using the following equation
Fc~F0
antilog(AexzAem)
2
  
ð1Þ
where F0 is the observed fluorescence, Fc is the corrected
fluorescence, Aex and Aem are the absorbances of the drug at
the excitation and emission wavelength.
Urea induced unfolding was used to study the stability of
different isomers of HSA (N, B and F) in the absence and presence
of virstatin (HSA/virstatin=1: 1 molar ratio). Stock solution of
urea (10 M) was prepared and then aliquots were used to prepare
a series of solutions containing different concentrations of urea.
The final solution mixture was incubated overnight at room
temperature.
Binding of Virstatin to HSA by ITC
Isothermal Titration Calorimetry allows the measurement of
the magnitude of the binding affinity, and the two contributing
thermodynamic terms: enthalpy (DH) and entropy (DS) changes
[23,24]. The binding of virstatin to the two different conforma-
tional forms of HSA (N and B) was studied by ITC, carried out on
a VP-ITC (Microcal Inc., Northampton, MA) at 30uC. Protein
solutions in different buffers (0.1 M potassium phosphate, pH 7.2
and 9.0, respectively) were dialyzed extensively before injecting.
The sample cell (approximately 1.4 mL) was loaded with HSA
(conc. 57 mM) and virstatin (conc. 600 mM) was injected into the
reaction cell. The titration cell was stirred continuously at
310 rpm, which ensured rapid mixing but did not cause foaming
on the protein solution. Titrations were performed to ensure full
occupancy of the binding sites and until the titration signal was
constant. The calorimetric data were analyzed using the MicroCal
Origin 7.0 software provided with the instrument. The enthalpy
change for each injection was calculated by integrating the area
under the peaks and then subtracted with control titrations. The
other thermodynamic parameters were calculated according to the
formulas
DG~{RT lnKa~DH{TDS ð2Þ
where T is the absolute temperature (303 K) and
R=8.3151 J mol
1 K
1.
Circular Dichroism (CD) Measurements and Thermal
Unfolding
CD measurements were carried out with a JASCO spectropo-
larimeter (model J-800) equipped with a thermoelectrically
controlled cell holder under a constant nitrogen flow. Cuvettes
with path lengths of 1 mm were employed for far-UV (200–
260 nm) and 5 mm for near-UV (240–310 nm) measurements,
with HSA concentrations of 10 mM and 1.5 mg/mL, respectively.
Each spectrum was the average of three scans. Far-UV CD spectra
were collected with a step resolution of 0.1 nm, a scan speed of
50 nm per minute and a bandwidth of 1 nm. All of the CD
measurements were carried out at 25uC.
During CD measurements, the DMSO (used as solvent for
virstatin) content never exceeded 1.5% (v/v). For the thermal
unfolding of HSA in presence and absence of virstatin, far-UV CD
spectra were recorded as a function of temperature between 20
and 80uC in steps of 2uC with an equilibration time of 2 min at
each temperature. The observed ellipticities were converted into
Figure 1. Chemical structure of virstatin.
doi:10.1371/journal.pone.0037468.g001
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2.dmol
21] which is given
by
½h222 ~100 hMw=cln ð3Þ
where [h222] is the measured ellipticity in degrees, c is the protein
concentration in mg/mL, l is the path length in cm, Mw is the
molecular weight of HSA and n is the number of amino acid
residues of HSA. Considering that the unfolding of the HSA is a
two-state process between folded F and unfolded U, the
equilibrium constant K at any temperature T can be written as,
K~
½F 
½U 
ð4Þ
where [F] and [U] are the concentrations of the folded and
unfolded forms, respectively. The equilibrium constant K is
related to the Gibbs free energy of unfolding as
DG~{RT lnK ð5Þ
where R is the gas constant and T is the absolute temperature.
Again the fraction folded at any temperature a is given by
a~
½F 
½F z½U 
ð6Þ
which is K=(1zK) and
a~
hT{hU
hF{hU
ð7Þ
where hT is the observed ellipticity at any temperature T, hF is the
ellipticity of the fully folded form and hU is the ellipticity of the
unfolded form. The temperature dependence of the secondary
structure was estimated from fitted far-UV CD curves by plotting
[h222] as a function of temperature T, using Gibbs-Helmholtz
equation
DG~DH 1{T=TM ðÞ
{DCpTM 1{ T=TM ðÞ z T=TM ðÞ ln T=TM ðÞ ½ 
ð8Þ
where TM is the melting temperature, DH is the change in
enthalpy and DCp is the change in specific heat capacity from the
folded to the unfolded state.
Fourier Transform Infrared (FT-IR) Spectroscopy
FT-IR spectra were recorded on a Perkin-Elmer spectrometer
equipped with a DTGS KBr detector and a KBr beam splitter. All
the spectra were taken via the absorbance mode with constant
nitrogen purging. Spectra were obtained at 4 cm
21 resolution with
50 scans. Spectra of background were collected and subtracted
from the original protein spectra. If not specifically mentioned, all
the spectra were collected in the range of 1400–1800 cm
21.
Computational Modeling of the HSA-virstain Complex
Virstatin was docked to the structure of HSA using PATCH-
DOCK and GOLD [25,26]. Hydrogen bonding was checked
between the protein and the ligand using HBPLUS [27]. The
accessible surface area was calculated using NACCESS [28].
Results and Discussion
UV Absorption Spectra of HSA in the Presence of Virstatin
The UV absorption spectra of HSA, virstatin and HSA
bound to virstatin were studied at physiological pH (pH 7.2)
and are shown in Figure 2. Virstatin has a characteristic peak at
345 nm. However, there was no absorption of HSA alone in
this range (400–300 nm), as proteins do not have significant
absorbance beyond 300 nm. Upon binding to HSA the
wavelength, shape and intensity of the absorption band of the
drug changes, with the concomitant appearance of two new
peaks at 329 and 360 nm. This can be seen clearly in the
difference spectrum (inset, Figure 2).
Characterization of Different Conformational States of
HSA and Analysis of Urea-induced Equilibrium Unfolding
Data
The fluorescence emission spectra for different conformers of
HSA were recorded in the absence and the presence of virstatin.
For native HSA (N and B conformers), the lmax were found to be
almost the same (348 nm), whereas for the F form the value of was
blue shifted (344 nm) (data not shown). It is likely that at pH 3.5,
the environment around the lone Trp becomes more hydrophobic.
For all the conformers of HSA (N, B and F) the fluorescence
intensity decreases and the spectra are characterized by significant
red shift in the presence of 5 M urea indicating the exposure of the
sole Trp residue to the aqueous medium [29].
The effect of virstatin binding on the stability of different
isomers of HSA was investigated by urea-induced unfolding at
various denaturant concentrations. The equilibrium unfolding was
monitored by the measurement of fluorescence emission at
340 nm after exciting the protein at 295 nm. Since HSA contains
only one tryptophan residue (Trp214), which resides in domain II,
the changes in fluorescence intensity may be ascribed to the
conformational changes in this domain. The plots of the ratio of
fluorescence emission intensity (F350/F340) for free HSA (N, B and
F states), as well as HSA-virstatin complex against urea
concentration yielded sigmoidal transition curves (Figure 3).
Figure 2. UV absorption spectra of virstatin before and after
interacting with HSA in potassium phosphate buffer pH 7.2.
The difference spectrum (complex – virstatin) is shown in the inset.
doi:10.1371/journal.pone.0037468.g002
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two-state transition between the folded (F) and the unfolded (U)
states. At each urea concentration the observed signal S,
representing the ratio of fluorescence emission intensity (F350/
F340) were fitted to a two state equation as shown below
S~
SFe
DGFU
RT
  
zSU
e
DGFU
RT
  
z1
ð9Þ
At each step the free energy change is assumed to be a linear
function of concentration of urea. The plots of DGFU (the
unfolding free energy) against urea concentration were analyzed
using the equation:
DGFU~DG
H2O
FU {mFU½dFU 1=2 ð10Þ
where mFU is the dependency of the DGFU on urea concentra-
tion, which is a measure of co-operativity of unfolding and
DGFU
H
2
O is the free energy change in the absence of denaturant,
which is equivalent to the conformational stability of the protein.
Dividing DGFU by the slope gives the value for the midpoint of
transition, [dFU]1/2.
The result shows that upon binding to the drug (HSA:virstatin
in 1:1 molar ratio) the unfolding free energy DGFU increases
compared to that for the free protein, indicating a stabilizing effect
of virstatin on HSA (Table 1). The values of the urea
concentration at half-completion of the transition, indicated as
[dFU]1/2, were found to be 3.68 M for the free HSA at pH 7.2,
which increases to 5.68 M for the HSA-virstatin complex. Similar
trends were also observed for the B and F forms of HSA. So
irrespective of pH, the binding of virstatin (in 1:1 molar ratio)
makes the protein more stable, as evident from the values of the
change in free energy of unfolding as well as the values of the
midpoint of transition.
Figure 3. Urea induced unfolding of (a) N, (b) B and (c) F isomers of HSA in the absence (solid symbols) and the presence (open
symbols) of virstain. The spectra overlaid along with the best-fit curves assuming a two-state model. F340 and F350 in the y-axis correspond to the
fluorescence intensities at the respective wavelengths.
doi:10.1371/journal.pone.0037468.g003
Table 1. Unfolding of different conformational isomers for
HSA alone and HSA bound to virstatin.
pH
GFU
kcal.mol
21
mFU
kcal.mol
21.M
21 [dFU]1/2 M
HSA (N) 7.2 1.4360.40 0.3960.08 3.68
HSA + virstatin 7.2 2.5460.35 0.4560.07 5.68
HSA (B) 9.0 2.2960.35 0.4360.08 5.29
HSA+virstatin 9.0 3.7660.60 0.6660.12 5.71
HSA (F) 3.5 2.9360.40 0.860.09 3.66
HSA + virstatin 3.5 3.0360.34 0.7560.10 4.04
Based on data shown in Figure 3.
doi:10.1371/journal.pone.0037468.t001
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by Virstatin and the Calculation of the Binding
Parameters
The quenching of fluorescence of proteins may be used as an
effective tool to derive information about protein-drug interaction
[30,31]. From the Stern-Volmer plot it is evident that the
increasing concentration of virstatin caused quenching of Trp
fluorescence for all conformational isomers of HSA (Figure S1).
As there is a downward curvature in the Stern-Volmer plot,
especially for the B form, we used modified Stern-Volmer plot
(Figure 4) and obtained the KSV values [29], which are 1.13610
5,
1.76610
5 and 0.43610
5 M
21 for N, B and F conformers of HSA,
respectively. The values are in accordance to the ones obtained
from ITC (discussed later). Competition studies between warfarin
and virstatin were attempted using fluorescence quenching
technique to determine the relative sites of their binding to
HSA, but did not succeed as both warfarin (excitation at 343 nm)
and virstatin (at 310 nm) fluoresce around the same wavelength
(emission at 390 nm).
Bis-ANS Binding Studies
Bis-ANS is widely used as hydrophobic fluorescent probe and
hence extensively used to examine the non polar character of protein.
A similar molecule, ANS has been shown to bind mainly to HSA
subdomain IIIA [32]. We wanted to see if the binding of virstatin has
any effect on the fluorescence spectra of bis-ANS bound to HSA.
Indeed, there is a decreasein fluorescence intensity of bis-ANS bound
HSA on addition of virstatin (Figure 5). It is possible that the changes
in conformation of HSA induced by the binding of virstatin (discussed
later) cause the quenching of bis-ANS fluorescence.
Tryptophan Fluorescence Resonance Energy Transfer
(FRET) from HSA to Virstatin
According to Fo ¨rster’s nonradiative energy transfer theory, the
energy transfer is possible when the fluorescence emission
spectrum of the donor and UV absorption spectrum of the
acceptor have suitable overlap, and the donor and the acceptor are
within the characteristic Fo ¨rster distance [29]. The fluorescence
spectra of HSA (7.5 mM) and absorption spectra of virstatin
(7.5 mM) were scanned between 300 to 450 nm. The spectral
overlap of the donor (W214 of HSA) and acceptor virstatin is
shown in Figure 6. The efficiency of energy transfer (E)i s
calculated using the following equation
Figure 4. Modified Stern-Volmer plot of the HSA virstatin
complex.
doi:10.1371/journal.pone.0037468.g004
Figure 5. Fluorescence quenching spectra of bis-ANS bound HSA in absence (top) and presence (the arrow indicating curves
obtained with increasing concentration) of virstatin in phosphate buffer pH 7.2; [HSA]=7.5 mM, [bis-ANS]=5.0 mMa n d
[virstatin]=0.1 to 5.0 mM (with 10 increments of 0.1 mM, followed by another 5 of 1 mM).
doi:10.1371/journal.pone.0037468.g005
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F
F0
~
R6
0
R6
0zr6 ð11Þ
Where F and F0 are the fluorescence intensities of HSA in the
presence and absence of virstatin, r is the distance between the
acceptor and the donor, and R0is the critical distance when the energy
transfer efficiency is 50%. R0 can be calculated using the equation
R6
0~8:79|10{25K2n{4wJ ð12Þ
Where K
2 is the spatial factor of orientation, n is the refractive
index of the medium and w is the fluorescence quantum yield of
the donor. The overlap integral of the fluorescence emission
spectrum of the donor and absorption spectrum of the acceptor, J
is calculated from the equation
J~
Ð ?
0
F l ðÞ el ðÞ l
4dl
Ð ?
0
F l ðÞ dl
ð13Þ
Where F(l) is the fluorescence intensity of the donor at wavelength
range l to l+Dl which is dimensionless, and e(l) is the extinction
coefficient of the acceptor at wavelength l in M
21 cm
21. In our
present study K
2,w and n were taken as 2/3, 0.118 and 1.336
respectively. The value of r is 3.05 nm from Eq. 11 using E=0.3.
The donor to acceptor distance being within the range of 0.5–2.0
R0 is indicative of an efficient energy transfer from HSA to
virstatin. This is further confirmed from the range of r which does
not exceed the dimensions of HSA (86863 nm) indicating transfer
of energy. However the values of R0 and r are possibly affected by
several factors when calculated by FRET theory and hence must
be considered as an apparent measure of the protein-drug binding
event [33].
Isothermal Titration Calorimetry of N and B Isomers of
HSA with Virstatin
In the present study, ITC was used to monitor the binding of
virstatin to HSA and to quantify the corresponding thermody-
namic parameters. Since ITC can be carried out at higher
concentrations of both the protein and ligands, it may comple-
ment fluorescence studies, especially for weakly binding probes
[34]. It is well reported in literature that the transport function of
HSA is controlled through the N-B transition of this protein,
which occurs between pH 7.0 and 9.0 [11,15]. Hence in the
present work the N and B conformational isomers of HSA were
chosen for binding study with virstatin (Figure 7). The final data
were fitted to a one-binding site model and the derived
parameters are shown in Table 2. The data revealed that the
binding of virstatin to different conformational isomers of HSA
(N form and B form) shows a favorable enthalpy change (DH ,0)
and an unfavorable entropy change (DS ,0). The ligand
polarizability in binding to a protein contributes to large negative
thermodynamic parameters. DH and DS both being negative in
this case signifies favorable non-covalent interactions, viz.,
electrostatic, H-bonding and van der Waals between the protein
and the drug. From the values of the binding constants (Ka), the
stabilities of the N-virstatin and B-virstatin complexes are
comparable. With similar binding constants for the N and B
isomers the distribution of virstatin in the body is not likely to be
affected by the proportion of isomeric forms of HSA.
In order to compare the binding affinities with warfarin the
ITC measurements were also carried out to the N and B
conformers of HSA (Figure S2 and Table 2). The binding
constants for HSA-warfarin complexes were found to be less in
comparison to the HSA-virstatin complex, especially for the B
Figure 6. Spectral overlap between fluorescence emission spectrum of HSA (solid line; lex 295 nm) and UV absorption spectrum of
virstatin (dotted line).
doi:10.1371/journal.pone.0037468.g006
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DH and DS values between the two ligands, as well as between
the two forms of HSA. It is well documented in literature that
warfarin binds to subdomain IIA of HSA and shares this binding
site with a range of other drugs, viz., phenylbutazone, tolbuta-
mide and indomethacin, and thus competes with them for
binding [35,36]. It was also found from docking studies (discussed
later) that virstatin shares the same binding site as that of warfarin
(site I, subdomain IIA).
Figure 7. ITC data for the titration of (a) the N and (b) the B forms of HSA with virstatin. Flow of heat with time during the injection of the
drug and the heat evolved per mole of added drug for each injection, shown at the top and the bottom, respectively.
doi:10.1371/journal.pone.0037468.g007
Table 2. Thermodynamic parameters derived from ITC
measurements on the binding of virstatin and warfarin with
different conformers of HSA.
Thermodynamic parameters N form B form
n (Virstatin : HSA stoichiometry) 0.2960.01 0.3360.02
[0.9660.02] [0.860.03]
Ka (binding constant) M
21 (6.0960.87)610
5 (4.4760.54)610
5
[(3.1860.54)610
5] [(7.7661.2)610
4]
DH (enthalpy) kcal mol
21 225.860.15 214.160.15
[210.860.03] [215.560.09]
S (entropy change) cal mol
21?K 258.79 220.79
[210.60] [228.75]
G (free energy change) kcal mol
21 27.99 27.80
[27.32] [26.07]
Values for warfarin are in square brackets.
doi:10.1371/journal.pone.0037468.t002
Figure 8. Far-UV CD spectra of the N isomer (pH 7.2) in the
presence of virstatin, with HSA/virstatin molar ratios of 1:1, 1:2
and 1:3.
doi:10.1371/journal.pone.0037468.g008
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Conformations of HSA
To explore various aspects of protein structure and also its
interaction with small molecules, CD is one of the strong and
sensitive spectroscopic tools [37,38]. The conformational changes
in the secondary structure of HSA have been studied with far- UV
CD, in the range of 200–260 nm at pH 7.2, 9.0 and 3.5 (Figure
S3). The CD spectra of HSA at physiological pH exhibits two
negative bands in the ultraviolet region at 208 nm (pRp *
transition) and 222 nm (nRp * transition) which is the charac-
teristic of a-helical protein [39]. The N (pH 7.2), B (pH 9.0) and F
(pH 3.5) conformational states of HSA contained 60.2%, 53.4%
and 48.5% of a-helix which is in agreement with the values
reported by other investigators [40]. The significant loss of helix
content for the F form may be due to the disruption of the intra-
domain and the inter-domain (II and III) structures at pH 3.5.
To study the influence of virstatin on the secondary structure of
HSA, the far-UV CD spectra were recorded using various molar
ratios of drug to protein (0, 1:1, 2:1 and 3:1) (Figure 8). For all
conformational states of HSA (N, F and B), there was an increase
of a -helical content at the expense of random coil when virstatin
binds to protein in 1:1 molar ratio (Table 3). Further increase in
the concentration of virstatin (2:1 and 3:1) has a deleterious
consequence on the secondary structure (especially, helix) of HSA
with a concomitant increase in the percentage of random coil. The
perturbation of the secondary structure of HSA in the presence of
higher concentration of virstatin has also been noted with other
drugs [41,42].
Temperature denaturation of protein results from the weaken-
ing of interactions, such as hydrogen bonding [43]. In the present
study the thermal unfolding of N, B and F conformers of HSA
alone, as well as, in the presence of virstain was carried out and the
shape of the melting curves conforms to two step transition from
the native to the unfolded state (Figure 9). The CD value (h222)
decreases with the rise in temperature, which may be due to a loss
of higher order secondary structure, i.e., a -helix with the
concomitant increase of random coil content [44]. This finding
is consistent with the characteristics of HSA at higher temperature
where the free sulfhydryl group at Cys34 exchanges with other
disulfide bridges [45,46]. The midpoint of the unfolding transition
(TM) determined from sigmoidal fits showed that upon binding to
virstatin the value of TM increased for the N isomer as compared
to the free HSA. The values of TM for N, B and F conformers of
HSA were found to be 68.6, 71.2 and 51.0uC, whereas in presence
of drug the TM values were 69.5, 71.9 and 51.7uC, respectively
(Figure 9, Figure S4).
FT-IR Spectra of HSA-virstatin Complexes
Infrared spectroscopy has been used as a powerful tool to
understand the secondary structures of proteins [47]. In the IR
region, the frequencies of bands due to the amide I–III vibrations,
particularly the amide I band, are sensitive for the prediction of
secondary structure of proteins. Hence to further prove the
conformational change of HSA induced by the binding of
virstatin, we investigated the FT-IR spectra of HSA and the
Table 3. Secondary structural content of HSA upon interaction with virstatin in different molar ratios.
Molar ratio (HSA
to virstatin) N form (pH 7.2) B form (pH 9.0) F form (pH 3.5)
a-helix
(%)
b-sheet
(%)
Random
coil (%)
a –helix
(%)
b-sheet
(%)
Random
coil (%)
a –helix
(%)
b-sheet
(%)
Random
Coil (%)
0 60.2 20.8 19.0 53.4 22.7 21.6 48.5 25.4 24.4
1:1 63.4 19.3 16.5 64.5 18.7 14.4 64.0 19.5 17.4
1:2 57.1 21.6 21.3 50.7 20.3 28.5 55.0 22.6 21.3
1:3 50.4 24.3 24.5 43.6 14.5 39.5 31.2 24.6 44.6
Data were deconvoluted using CDNN software (http://bioinformatik.biochemtech.uni-halle.de/cdnn).
doi:10.1371/journal.pone.0037468.t003
Figure 9. Temperature-induced denaturation of the N con-
former of free HSA (solid circle) and in the presence of virstatin
(open circle).
doi:10.1371/journal.pone.0037468.g009
Figure 10. FT- IR spectra of free HSA (blue) and HSA -virstatin
complex (red) in D2O in the range of 1720 to 1560 cm
21.
doi:10.1371/journal.pone.0037468.g010
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region 1600–1700 cm
21 and the amide II band at 1548 cm
21.I n
general, the range 1650–1660 cm
21 in the amide I band can be
attributed to a -helix [48]. In the present study the FT-IR spectra
of free HSA as well as virstatin bound HSA was carried out in
D2O (Figure 10). The characteristic amide I and amide II bands
for free HSA were found at 1651 and 1567 cm
21, respectively.
The peak position of amide I moved from 1651 cm
21 to
1648 cm
21, and for amide II from 1567 cm
21 to 1562 cm
21 on
complexation with virstatin. This may be due to the change in
secondary structure of HSA after interaction with virstatin,
resulting in the perturbations of the amide I and amide II
vibrational frequencies.
Near-UV CD Spectroscopy
Near-UV CD spectroscopy may be employed to detect
asymmetry in the environment of aromatic residues and hence is
a sensitive tool to measure minor structural perturbations in
proteins [49]. Each of the amino acids has characteristic
wavelength range, e.g. tryptophan shows fine structures between
Figure 12. Cartoon representation of HSA with the bound virstatin (red). Trp214 is shown in golden sticks. In (a) the N- and the C-termini of
the polypeptide chain are shown as red and blue balls, respectively. (b) Close-up view of virstatin (N is in blue, O in red, H is in grey and the rest are C
atoms) with two short contacts with Trp214 shown. (c) The cavity corresponding to site I with bound virstatin. The details of the relative positions of
the neighboring residues (Table 4) are shown in Figure S5. The figures are made with PYMOL (http://www.pymol.org).
doi:10.1371/journal.pone.0037468.g012
Figure 11. Near-UV CD spectra of the N form of HSA in the
absence and the presence of virstatin.
doi:10.1371/journal.pone.0037468.g011
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phenylalanine shows weaker bands around 255 to 270 nm [50].
The near-UV CD spectra were measured in the range of 250 to
300 nm for different isomers of HSA (N, B and F) and also in the
presence of virstatin (Figure 11 and Figure S5). For the N
conformer (pH 7.2) the appearance of two minima at 263 and
269 nm and shoulders at 273 and 291 nm indicate the charac-
teristics of disulfide and aromatic chromophores, similar to earlier
reports. The reduction of CD signal for the B isomer may be due
to the fact that during the N-B transition, alteration of tertiary
structure of domain I occurred. For the F isomer the signal was
further reduced, indicating perturbations around the Trp residue
and the disulfide bridges. After binding to virstatin, which itself
is an achiral molecule and does not exhibit any CD signal, the
near-UV CD spectra of different conformers of HSA showed
significant alteration of tertiary structure [51].
Molecular Docking Study of HSA-virstatin Interaction
In order to understand the efficacy of a drug as a therapeutic
agent, it is necessary to explore the binding site of that drug in
proteins. HSA contains three predominantly helical structural
domains, each of which is made up of two subdomains having
specific structural and functional characteristics. The two main
binding sites, namely sites I and II (hydrophobic in nature), are
located in subdomains IIA and IIIA, respectively. Site I is known
as the warfarin binding site, and prefers to bind large heterocyclic
and negatively charged compounds, while site II is suitable for
small aromatic carboxylic acids [14,52].
The binding region of virstatin to HSA obtained from both the
docking programs, PATCHDOCK and GOLD [25,26], is very
similar and corresponds to the site I. However, while the solution
from PATCHDOCK showed no hydrogen bond, the one from
GOLD had 3 hydrogen bonds, but with the n-butyric acid side
chain folded over to the top of the cyclic structure. With a more
extended side chain and an overall greater non-polar contact the
solution from PATCHDOCK was considered for further analysis
(Figure 12a). Figure 12b shows the contacts between virstatin and
tryptophan residue (Trp214) which are within 5 A ˚. The cavity
corresponding to site I with bound virstatin is shown in Figure 12c.
There are 14 surrounding residues, seven nonpolar and seven
charged; Arg257 is the closest with NE at a distance of 2.95 A ˚
(Figure S6) from O1 of virstatin (the same pair was found to form a
hydrogen bond in docked structure obtained from GOLD). Also
hydrogen bonding between ligand and Arg257 has reported in
other HSA-drug binding studies, indicating a possible electrostatic
component in the interaction between virstatin and HSA. The
accessibility of the sole tryptophan residue got reduced by 4.4 A ˚ 2
after docking with virstatin. Apart from Trp214, the accessibility
gets reduced for 21 other residues which include all (except
Phe211) used for warfarin binding at site I as reported in [53] and
none of the residues from site II binding region (Table 4). We also
used a recently developed albumin binding prediction webserver
(http://albumin.althotas.com) [54], which also predicted the
binding site of virstatin to be more similar to the ligands known
to bind at site I rather than at II. Table S1 indicates that 96.4% of
the surface area of virstatin gets buried on complex formation.
Virstatin has been found to prevent the intestinal colonization of
V. cholerae [6]. It has also been shown to interact with two V. cholerae
proteins, ToxT and Ace, associated with the virulence activity of
the organism [7,9]. For the development of the molecule as drug it
is important to understand its biodistribution. In this paper the
interaction between HSA and virstatin has been studied using
various biophysical methods. ITC revealed the binding of virstatin
with different conformers (N and B) of HSA. The binding was
found to be exothermic, located in site I corresponding to the
binding site of warfarin. On binding virstatin there are alterations
in the secondary and tertiary structures, as revealed by the far- and
the near-UV CD spectroscopy. Results from ITC experiment
showed comparable binding affinities for both the isomers. The
protein is stabilized, with higher helical content, against urea and
thermal unfolding in presence of virstatin in the molar ratio 1:1;
however, a higher concentration of virstatin seems to have a
destabilizing effect. The docked binding site of the molecule is
compared to other known drug binding sites and correlated with
spectroscopic data. The biological importance of this study lies in
understanding the interaction of HSA with virstatin, which will be
essential for the future designing of virstatin-inspired drugs.
Table 4. Change in accessibilities of residues at binding sites I
and II on binding different ligands.
Ligands Amino acid residue DASA (A ˚2)
b
Virstatin Tyr150 15.72
Glu153 10.69
Ser192 14.9
Lys195 17.34
Lys199 21.69
Leu219 12.49
Arg222 13.39
Leu238 29.68
Arg257 13.08
Leu260 11.11
Ile264 10.07
Ile290 13.54
Ala291 34.68
Glu292 13.57
Warfarin
a Leu238 39.03
Ala291 38.6
Leu242 35.6
Trp214 28.93
Arg257 16.4
Arg222 14.05
Leu219 12.25
Ser287 12.02
Ile290 11.48
Phe211 11.26
Leu260 10.72
Ibuprofen
a Leu453 28.22
Val485 27.55
Asn391 21.82
Leu387 19.4
Ile388 16.85
Pro384 10.79
Glu450 10.79
aValues for warfarin binding at Site I and ibuprofen binding at Site II are from
[53].
bDASA=ASA(isolated) – ASA(complex), where ASA is the accessible surface area
of a given residue. Only values .10 A ˚2 are reported.
doi:10.1371/journal.pone.0037468.t004
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